Degarelix

What is Degarelix?

Degarelix (brand name FIRMAGON, development code FE200486) is a synthetic decapeptide GnRH receptor antagonist approved by the FDA on December 24, 2008 for treatment of advanced hormone-dependent prostate cancer. Unlike GnRH agonists (leuprolide, goserelin, triptorelin), degarelix produces immediate testosterone suppression without an initial testosterone "flare".

Degarelix is administered as a monthly subcutaneous depot injection, with an initial 240 mg loading dose followed by 80 mg monthly maintenance.

Structure and Mechanism

Degarelix's peptide backbone incorporates several unusual amino acid building blocks (4-aminophenylalanine derivatives, homoorinithine, ureido modifications) designed for:

• High GnRH receptor affinity
• Antagonist (non-activating) binding
• Long subcutaneous depot half-life (~28-43 days)

The pharmacological advantage over agonists is the absence of testosterone flare:

• GnRH agonists initially activate the receptor, triggering a 1-2 week LH/testosterone surge before pituitary desensitization. In high-burden bony prostate cancer, this surge can cause spinal cord compression, urinary obstruction, and pain flares.
• GnRH antagonists like degarelix block the receptor immediately. Testosterone falls within 3 days to castrate levels (<50 ng/dL) without intermediate elevation.

For patients with widespread metastatic disease, this immediate suppression eliminates the need for concomitant anti-androgen therapy and reduces the risk of dangerous initial disease progression.

Clinical Evidence

Phase 3 head-to-head vs leuprolide (BJU 2008):

• 610 prostate cancer patients randomized to degarelix or leuprolide
• Testosterone suppression to castrate levels by day 3: 96% degarelix vs 0% leuprolide
• By day 28, both arms achieved equivalent suppression
• Higher PSA suppression at day 14 with degarelix
• No difference in long-term efficacy (months 6-12)

Subsequent observational and retrospective analyses have suggested possible cardiovascular benefit of degarelix vs GnRH agonists in patients with prior cardiovascular disease (PRONOUNCE Phase 3 trial 2021 was inconclusive on this point but did not show meaningful difference). Mechanism is debated but may relate to FSH receptor effects on cardiovascular tissue.

Approval History

• December 24, 2008 — FDA approval for advanced prostate cancer
• February 2009 — EMA approval

Place in Therapy

Degarelix is positioned as an alternative to GnRH agonists for advanced prostate cancer, with particular advantages in:

• Symptomatic spinal metastases — immediate suppression avoids agonist flare
• High-burden bone disease at risk for cord compression — same flare-avoidance rationale
• Patients with cardiovascular comorbidity — possible CV benefit signal (not proven definitively)
• Acute symptomatic obstructive uropathy — rapid testosterone drop

Disadvantages:

• Monthly dosing only (vs 3-, 6-, or 12-month GnRH agonist depots)
• Higher rates of injection-site reactions
• Higher cost in many formularies

Many oncology practices use degarelix for the first 1-3 months in high-risk patients, then transition to a longer-acting GnRH agonist depot for chronic suppression.

Safety Profile

Most common adverse events:

• Injection-site reactions — substantially more common than with agonist depots (~40% vs ~5%); usually erythema, induration, or pain at the SC depot site
• Hot flashes (class effect)
• Increased weight, fatigue, decreased libido
• Hepatic enzyme elevations
• Decreased bone mineral density with prolonged use

The injection-site reactions reflect the local depot pharmacology and are typically mild but persistent over the dosing cycle.

Distinction from Other GnRH Drugs

Degarelix is the only GnRH antagonist depot approved for chronic use in oncology.